AIDS Rev. 2008;10(3):152-161. In patients with HIV-related lipodystrophy (assessed by patients and confirmed by physicians), Marin, et al. have recently validated a new questionnaire consisting of ...

Together, these issues make it difficult to know how these study findings translate to individualized management for most patients with HIV-related lipodystrophy.

Other factors related to the individual’s health and specifically to HIV may also play a role in the development of lipodystrophy. These include duration of HIV therapy, duration of HIV infection, ...

Novelion Therapeutics’ Myalepta (metreleptin) developed for the ultra-rare condition lipodystrophy has been approved by the European Commission, giving patients the first treatment to improve ...

Egrifta SV is used to reduce excess abdominal fat in adults with HIV and lipodystrophy. Theratechnologies (THTX) said in December that production of the drug had resumed following a voluntary ...

Theratechnologies said Thursday that patients will encounter a shortage of Egrifta SV--its prescription medicine that reduces excess belly fat in adults with HIV and lipodystrophy--in mid-January.